Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A new CMF regimen

R Demicheli, V Fossati, G F Garusi

    Tumori
    |December 31, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Oral cyclophosphamide (CTX) causes gastric issues, leading to erratic dosing and reduced chemotherapy effectiveness. Intravenous CTX administration is proposed to improve treatment consistency and efficacy, with data on its mild toxicity presented.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy.

    Annals of oncology : official journal of the European Society for Medical Oncology·2024
    Same author

    Mitochondria in Multiple Sclerosis: Molecular Mechanisms of Pathogenesis.

    International review of cell and molecular biology·2017
    Same author

    Is there a rationale for an anesthesiologist's role against cancer recurrence?

    Acta anaesthesiologica Belgica·2013
    Same author

    A clinical-study of immunotherapy versus endocrine therapy versus chemotherapy in the treatment of advanced pancreatic adenocarcinoma.

    Oncology reports·2011
    Same author

    Gene regulatory networks: a new conceptual framework to analyse breast cancer behaviour.

    Annals of oncology : official journal of the European Society for Medical Oncology·2010
    Same author

    Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer.

    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica·2008
    Same journal

    End-of-life decisions and opinions: Results of E.L.D.Y.-CA.RE study carried out at Veneto Institute of Oncology, Italy.

    Tumori·2026
    Same journal

    Quality indicators in identification and care of patients with genetic predisposition to cancer: An AIFET proposal.

    Tumori·2026
    Same journal

    Driver vs. passenger: Primary resistance to larotrectinib in synovial sarcoma harboring concurrent SS18 rearrangement and PDE3A-NTRK2 fusion.

    Tumori·2026
    Same journal

    Beyond the calendar: A narrative review on chronobiological drivers of prognosis in resectable NSCLC.

    Tumori·2026
    Same journal

    Challenging the cornerstone: Toward risk-adapted follow-up in early breast cancer.

    Tumori·2026
    Same journal

    Assessing in house comprehensive genomic profiling by liquid biopsy for NSCLC patients.

    Tumori·2026
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Gastric disturbances from oral cyclophosphamide (CTX) in CMF regimens often lead to inconsistent patient dosing.
    • Erratic administration, dose reduction, or divided doses of oral CTX introduce uncertainty in treatment outcomes.
    • This inconsistency can potentially decrease the overall effectiveness of chemotherapy.

    Purpose of the Study:

    • To propose and examine the rationale for intravenous (i.v.) administration of cyclophosphamide (CTX).
    • To address the challenges posed by oral CTX-induced gastric disturbances in cancer treatment regimens.
    • To present initial data on the toxicity profile of the proposed i.v. CTX schedule.

    Main Methods:

    • Review of existing data and clinical observations regarding oral cyclophosphamide administration in CMF regimens.

    Related Experiment Videos

  • Development of a proposal for an alternative intravenous administration schedule for cyclophosphamide.
  • Collection and reporting of preliminary toxicity data for the intravenous cyclophosphamide schedule.

    • Main Results:

    • Oral cyclophosphamide often leads to patient-reported gastric issues, impacting adherence and dosing consistency.
    • The proposed intravenous cyclophosphamide administration aims to mitigate these gastric disturbances.
    • Initial data indicate a mild toxicity profile for the intravenous cyclophosphamide schedule.

    Conclusions:

    • Intravenous cyclophosphamide administration offers a potential solution to improve treatment adherence and consistency in CMF regimens.
    • Mitigating gastric disturbances associated with oral CTX may enhance chemotherapy effectiveness and reliability.
    • The proposed i.v. schedule demonstrates a mild toxicity profile, warranting further investigation.